Pancreatic cancer records often combine chemotherapy backbones with newer targeted or immune approaches, or they study earlier detection in high-risk families. Eligibility is usually strict about stage, bilirubin, and prior regimens. Use the NCT link as the source of truth. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
RecruitingPhase 2Bethesda, Maryland
Phase 2: testing Pembrolizumab (Keytruda) for Metastatic Colorectal CancerBackground: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma.
NCT01174121 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 1Chapel Hill, North Carolina
Phase 1: testing Ulixertinib for Tumor, SolidThis phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.
NCT03454035 · Official ClinicalTrials.gov record · UNC Lineberger Comprehensive Cancer Center
RecruitingPhase 2Loma Linda, California
Phase 2: testing Gemcitabine 1000 mg for Pancreas AdenocarcinomaThe purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel.
NCT03492671 · Official ClinicalTrials.gov record · Loma Linda University
RecruitingPhase 1Fairway, Kansas
Phase 1: testing Metarrestin for Advanced Solid TumorsBackground: Metastasis is the spread of cancer from one organ to a nonadjacent organ. No treatment specifically prevents or reduces metastasis.
NCT04222413 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 2Anchorage, Alaska
Phase 2: testing Olaparib for Pancreatic Acinar Cell CarcinomaThis phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged.
NCT04858334 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: EUS-CPN without bupivacaine for Pancreatic CancerEndoscopic ultrasound (EUS) allows EUS-guided trans gastric injection of absolute alcohol around the base of the celiac plexus (celiac plexus neurolysis (EUS-CPN)), to help alleviate pain associated with pancreatic cancer. It is standard procedure to inject bupivacaine immediately before injecting absolute alcohol, to theoretically prevent pain that may occur during and after the procedure.
NCT04951804 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)
RecruitingNot a traditional drug phaseAnchorage, Alaska
Not a traditional drug phase: Questionnaire Administration for Acute Lymphoblastic LeukemiaThis study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
NCT05334069 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
RecruitingNot a traditional drug phaseDuarte, California
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseThis is an watch-and-measure (no experimental treatment required) case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid.
NCT05366881 · Official ClinicalTrials.gov record · Adela, Inc
RecruitingPhase 1Aurora, Colorado
Phase 1: testing TTI-101 for Pancreatic CancerThe survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial invigoration of immune response, and relief of symptom burden, SBRT has not demonstrated any improvement in survival. Preclinical research has established that STAT3 inhibition given concurrently with SBRT and in the maintenance phase acts as a synergistic agent that enhances the pro-inflammatory effects of SBRT while reducing its undesired effects (including fibrosis and immunosuppression).
NCT06141031 · Official ClinicalTrials.gov record · Washington University School of Medicine
RecruitingPhase 1Scottsdale, Arizona
Phase 1: testing Sofe-M for Ovarian NeoplasmsThis study wants to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion).
NCT06400472 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingPhase 1Duarte, California
Phase 1: testing LY4052031 for Metastatic Solid TumorThis study wants to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion).
NCT06465069 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingPhase 2Prescott, Arizona
Phase 2: testing Zanidatamab for Breast CancerThis study wants to measure the how well it works and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
NCT06695845 · Official ClinicalTrials.gov record · Jazz Pharmaceuticals
RecruitingPhase 2Birmingham, Alabama
Phase 2: testing BAY2927088 for Advanced Solid TumorsResearchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
NCT06760819 · Official ClinicalTrials.gov record · Bayer
RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Lanreotide for Pancreatic CarcinomaThis phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.
NCT06807437 · Official ClinicalTrials.gov record · SWOG Cancer Research Network
RecruitingPhase 1Bethesda, Maryland
Phase 1: testing cyclophosphamide for MesotheliomaBackground: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma.
NCT06885697 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 1 / Phase 2Los Angeles, California
Phase 1 / Phase 2: testing VS-7375 for Pancreatic Ductal AdenocarcinomaThis study will assess the safety and how well it works of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
NCT07020221 · Official ClinicalTrials.gov record · Verastem, Inc.
RecruitingNot a traditional drug phaseMinya
Not a traditional drug phase: pancreaticoduodenectomy procedure for Pancreas CancerPancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality. Postoperative pancreatic fistula (POPF) is the most common and clinically significant complication following PD.
NCT07022015 · Official ClinicalTrials.gov record · Minia University
RecruitingNot a traditional drug phaseDublin, California
Not a traditional drug phase: Exercise intervention for Localized Malignant Solid NeoplasmThis clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength.
NCT07059884 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
RecruitingPhase 1Duarte, California
Phase 1: testing PF-08046876 for Advanced/Metastatic Solid TumorsThe purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'.
NCT07090499 · Official ClinicalTrials.gov record · Pfizer
RecruitingNot a traditional drug phaseBoston, Massachusetts
Not a traditional drug phase: testing chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] for Pancreatic CancerThe purpose of this treatment clinical trial is to evaluate safety and how well it works of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.
NCT07325214 · Official ClinicalTrials.gov record · IMGT Co., Ltd.
RecruitingPhase 2San Francisco, California
Phase 2: testing Navlimetostat for Solid TumorsThis is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a this drug alone component and a combination component in which Navlimetostat (BMS-986504) is given with other anti-cancer agents.
NCT07492680 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
RecruitingPhase 3Huntsville, Alabama
Phase 3: testing Atebimetinib for Pancreatic CancerThis study wants to measure the safety and how well it works of atebimetinib in combination with modified GnP compared with SOC GnP alone.
NCT07562152 · Official ClinicalTrials.gov record · Immuneering Corporation
RecruitingPhase 1 / Phase 2Los Angeles, California
Phase 1 / Phase 2: testing ODM-212 for MesotheliomaAn open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
NCT07563738 · Official ClinicalTrials.gov record · Orion Corporation, Orion Pharma
RecruitingPhase 1 / Phase 2Pittsburgh, Pennsylvania
Phase 1 / Phase 2: testing Selumetinib for Advanced Pancreatic Ductal AdenocarcinomaThis phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment of pancreatic ductal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT07619521 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 3Phoenix, Arizona
Phase 3: testing Zoldonrasib for Pancreatic CancerThis study wants to measure the how well it works of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to dummy treatment (placebo) in combination with chemotherapy.
NCT07621718 · Official ClinicalTrials.gov record · Revolution Medicines, Inc.
RecruitingPhase 2Los Angeles, California
Phase 2: testing VS-7375 for Pancreatic Ductal Adenocarcinoma (PDAC)This study will assess the safety and how well it works of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
NCT07644559 · Official ClinicalTrials.gov record · Verastem, Inc.
RecruitingNot a traditional drug phaseBirmingham, Alabama
Not a traditional drug phase: INSPIRE (INtegrating Systematic PatIent-Reported Evaluations) for Breast CancerThe purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, measure the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.
NCT07671937 · Official ClinicalTrials.gov record · University of Alabama at Birmingham
RecruitingPhase 1 / Phase 2Chengdu, Sichuan
Phase 1 / Phase 2: testing SHR-1701 for Metastatic Pancreatic CancerThe goal of this clinical trial is to measure the safety and how well it works of GnP combined with SHR-1701 and Apatinib as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma.
NCT07802184 · Official ClinicalTrials.gov record · West China Hospital
RecruitingPhase 3Phoenix, Arizona
Phase 3: testing daraxonrasib for Pancreatic CancerThis study wants to measure the how well it works of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.
NCT07805954 · Official ClinicalTrials.gov record · Revolution Medicines, Inc.
RecruitingNot a traditional drug phaseHanoi, Hanoi
Not a traditional drug phase: IHC analysis for ENPP1, cGAS, and FAP expression for HCC - Hepatocellular CarcinomaThis Vietnam-based watch-and-measure (no experimental treatment required) study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor samples using immunohistochemistry (IHC). The study involves no investigational treatments or participant-facing procedures.
NCT07808164 · Official ClinicalTrials.gov record · Tam Anh Research Institute
RecruitingNot a traditional drug phaseGilbert, Arizona
Not a traditional drug phase: EUS-Guided MWA Device for Pancreatic CancerThe goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.
NCT07817147 · Official ClinicalTrials.gov record · Banner Health
RecruitingPhase 1The Bronx, New York
Phase 1: testing Lm-LLO-TT for Pancreas Cancer, Duct Cell AdenocarcinomaClinicalTrials.gov Brief Summary This Phase 1, open-label, first-in-human study is designed to measure the safety, tolerability, and recommended dose of intraperitoneal (IP) administration of Lm-LLO-TT in combination with low-dose gemcitabine in adults with previously treated, unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Lm-LLO-TT is a live attenuated Listeria monocytogenes-based immunotherapy engineered to express a tetanus toxoid antigen.
NCT07828236 · Official ClinicalTrials.gov record · Loki Therapeutics, Inc.
RecruitingPhase 1Oklahoma City, Oklahoma
Phase 1: testing modified FOLFIRINOX for Pancreatic Ductal Adenocarcinoma (PDAC)The purpose of this research is to observe the effects of using a new combination of drugs to inhibit tumor growth.
NCT07829185 · Official ClinicalTrials.gov record · University of Oklahoma
RecruitingNot a traditional drug phaseShanghai
Not a traditional drug phase: PET/CT with 18F-FDG and 68Ga-FAPI for Pancreas CarcinomaPancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis, and early detection of pancreatic lesions is of great importance for improving patient outcomes. In this study, whole-body imaging with FDG and FAPI will be used to visualize the early development of pancreatic cancer lesions from multiple perspectives, including glucose metabolism, tumor fibrotic stroma, and integrin receptor expression.
NCT07925125 · Official ClinicalTrials.gov record · Ruijin Hospital